InvestorsHub Logo
Followers 8
Posts 1891
Boards Moderated 0
Alias Born 05/05/2016

Re: SrdghJack post# 19236

Friday, 12/14/2018 11:31:26 AM

Friday, December 14, 2018 11:31:26 AM

Post# of 44784

like I said, I’m no expert.

Don't worry, "Auto1" IS, AND he doesn't get "CONSULTING FEES"! LOL! and he thinks Pluristem is going after the WRONG indications!!! .... really!!! Maybe the company should hire "Auto1" as a ........ CONSULTANT (but no fees, PLEASE!) LOL!

Good presentation. One more small piece of data that corroborates the Pluristem story. Perhaps the implications of success in CLI can be broadened to include a multitude of occlusive diseases... hmm, maybe CLI is a pretty good indication to start with!

The money issue is something we have to look at, but my feeling is that as the evidence of efficacy keeps coming in, the ability of the company to raise funds will improve substantially. The challenge for Pluristem is no different than any other small biotech, success in the clinic will translate into support from partnerships, grants and other means. I don't think it should be a major worry.